Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 10, 2026, reports the issuance of a press release containing financial results for the three and six months ended June 30, 2026. The registrant, Heron Therapeutics, Inc., is a Delaware corporation with its principal executive offices in Cary, NC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached "Earnings Press Release" (Exhibit 99.1), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes
The filing does not detail specific material changes versus prior periods. It serves solely as a notification that the company has announced its financial results for the specified periods.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. Such information is referenced as being included in the attached press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash burn figures for the three and six months ended June 30, 2026.
- Verify the company's cash position and runway as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the press release includes updated financial guidance or operational outlook.